MLN 2201

Drug Profile

MLN 2201

Alternative Names: Anti-b2 monoclonal antibody; Anti-CD18 monoclonal antibody LDP-01; LDP 01; MLN 01

Latest Information Update: 20 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 10 Oct 2003 Discontinued - Phase-I for Reperfusion injury in USA (unspecified route)
  • 10 Oct 2003 Discontinued - Preclinical for Reperfusion injury in United Kingdom (unspecified route)
  • 25 Jun 2003 Phase-I clinical trials in Reperfusion injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top